Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 15 11 2018
revised: 26 01 2019
accepted: 08 02 2019
pubmed: 1 5 2019
medline: 5 8 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

An association has been found between high anti-Müllerian hormone (AMH) levels during pregnancy and the development of polycystic ovary syndrome (PCOS)-like phenotypic traits in mouse offspring. The aim of this study was to determine whether AMH levels are associated with maternal testosterone levels, and whether high AMH concentration influences the risk of developing PCOS-related adverse pregnancy outcomes. Maternal serum AMH, testosterone and sex hormone binding globulin levels were measured in blood samples taken in early second-trimester pregnancies from women with PCOS (n = 159) and healthy controls matched for body mass index (n = 320). Possible associations with preeclampsia, gestational hypertension, gestational diabetes, preterm birth and birthweight was explored by logistic and linear regression models. Women with PCOS had higher AMH, higher total testosterone levels and higher free androgen index than controls (P < 0.001 for all three parameters). Among women with PCOS, high testosterone levels (B = 2.7; β = 0.26; P = 0.001) and low first trimester body mass index (B = -0.5; β = -0.17; P = 0.043) remained independently associated with AMH. High AMH levels were associated with decreased risk of gestational hypertension (adjusted OR 0.55; 95% CI 0.34 to 0.87), but no association was found with other adverse pregnancy outcomes or birthweight. Women with PCOS had higher AMH levels during pregnancy compared with controls, but high AMH was not associated with increased risk of adverse pregnancy outcomes or birthweight.

Identifiants

pubmed: 31036431
pii: S1472-6483(19)30101-4
doi: 10.1016/j.rbmo.2019.02.004
pii:
doi:

Substances chimiques

Testosterone 3XMK78S47O
Anti-Mullerian Hormone 80497-65-0
Luteinizing Hormone 9002-67-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-148

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Ragnheidur Valdimarsdottir (R)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden.

Heiddis Valgeirsdottir (H)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden.

Anna-Karin Wikström (AK)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden.

Theodora Kunovac Kallak (TK)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden.

Evangelia Elenis (E)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden.

Ove Axelsson (O)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden; Centre for Clinical Research Sörmland, Uppsala University Eskilstuna, Sweden.

Kumari Ubhayasekhera (K)

Department of Chemistry - BMC, Analytical Chemistry and Neurochemistry, Uppsala University Uppsala, Sweden.

Jonas Bergquist (J)

Department of Chemistry - BMC, Analytical Chemistry and Neurochemistry, Uppsala University Uppsala, Sweden.

Terhi T Piltonen (TT)

Department of Obstetrics and Gynaecology, University of Oulu and Oulu University Hospital, Medical Research Center, PEDEGO Research Unit Oulu, Finland.

Pascal Pigny (P)

Laboratoire de Biochimie & Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, CHU de Lille, Lille, France; Jean-Pierre Aubert Research Center (JPArc), Laboratory of Development and Plasticity of the Neuroendocrine Brain, Inserm, UMR-S 1172 Lille, France.

Paolo Giacobini (P)

Jean-Pierre Aubert Research Center (JPArc), Laboratory of Development and Plasticity of the Neuroendocrine Brain, Inserm, UMR-S 1172 Lille, France; University of Lille, FHU 1,000 Days for Health, School of Medicine Lille, France.

Inger Sundström Poromaa (IS)

Department of Women's and Children's Health, Uppsala University Uppsala, Sweden. Electronic address: inger.sundstrom@kbh.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH